Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

HER-2/neu

HER-2/neu or ERB-B2 Codes for a growth factor receptor Breast, salivary gland, prostate, bladder and ovarian cancers... [Pg.1279]

The pathologic evaluation of breast lesions serves to establish the histologic diagnosis and to confirm the presence or absence of other factors believed to influence prognosis. These prognostic factors include the presence of necrosis, lymphatic or vascular invasion, nuclear grade, hormone receptor status, proliferative index, amount of aneuploidy, and HER-2/neu expression. [Pg.1306]

HER-2/neu protein expression. Patients with HER-2/neu overexpression have a worse prognosis. [Pg.1308]

Trastuzumab is a monoclonal antibody directed against the HER-2/neu receptor. HER-2/neu is a member of the erbB (or HER) growth factor receptor family and is expressed at low levels in the epithelial cells of normal breast tissue. The overexpression of HER-2/neu is associated with increased transmission... [Pg.1313]

It should be noted that only 20% to 30% of patients with metastatic breast cancer overexpress HER-2/neu, and... [Pg.1320]

Rhodes A, Jasani B, Anderson E, et al. Evaluation of HER-2/neu immunohisto-chemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors a comparative study involving results from laboratories in 21 countries. Am. J. Clin. Pathol. 2002 118 408-417. [Pg.85]

Jacobs TW, Gown AM, Yaziji H, et al. HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry. A study of interlaboratory agreement. Am. J. Clin. Pathol. 2000 113 251-258. [Pg.99]

Konecny G,Thomssen C, Luck H, et al. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. J. Natl. Cancer Inst. 2004 96 1141-1151. [Pg.231]

Shin SJ, Chen B, Hyjek E, et al. Immunocytochemistry and fluorescence in situ hybridization in Her-2/neu status in cell block preparations. Acta Cytol. 2007 51 552-557. [Pg.231]

Beatty BG, Bryant R, Wang W, et al. Her-2/neu detection in fine-needle aspirates of breast cancer fluorescence in situ hybridization and immunocytochemical analysis. Am. J. Clin. Pathol. 2004 122 246-255. [Pg.234]

Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer prognostic factor, predictive factor, and target for therapy. Oncologist 1998 3 237-252. [Pg.367]

Ross JS, Fletcher JA, Bloom KJ, et al. Targeted therapy in breast cancer the HER-2/neu gene and protein. Mol. Cell. Proteomics 2004 3 379-398. [Pg.367]

Her-2/neu, Her-3, Her-4 heterodimers Overexpression Breast, ovary, lung, gastric cancers... [Pg.4]

Li WM, Dragowska WH, Bally MB, Schutze-Redelmeier MP. Effective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/ neu-derived peptide co-encapsulated in liposomes. Vaccine 2003 21(23) 3319-3329. [Pg.220]

Provinciali M, Papalini F, Orlando F, Pierpaoli S, Donnini A, Morazzoni P, Riva A, Smorlesi A. (2007) Effect of the silybin-phosphatidylcholine complex (IdB 1016) on the development of mammary tumors in HER-2/neu transgenic mice. Cancer Res 67 2022-2029. [Pg.174]

Tsai CM, Chang KT, Wu LH, Chen JY, Gazdar AF, Mitsudomi T, Chen MH, Perng RP (1996) Correlations between intrinsic chemoresistance and HER-2/neu gene expression, p53 gene mutations, and cell proliferation characteristics in non-small cell lung cancer cell lines. Cancer Res 56 206-209 Oberall F, Oberhuber H, Maly K, Zaknun J, Demuth L, Grunicke HH (1991) Hexade-cylphosphocholine inhibits inositol phosphate formation and protein kinase C activity. Cancer Res 51 807-812... [Pg.92]

Pietras RJ, Poen JC, Gallardo D, Wongvipat PN, Lee HJ, Slamon DJ. Monoclonal antibody to HER-2/ neu receptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res 1999 59 1347-1355. [Pg.250]

Formenti S, et al. Low HER 2/NEU Gene Expression is Associated with Pathological Response to Primary Paclitaxel and Radiation in Locally Advanced Cancer (LABC). Proceedings of ASTRO 2000 63. [Pg.250]

Pegram MD, Pauletti G, Slamon DJ. HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat 1998 52 65-77. [Pg.334]

Zhang L, Hung MC. Sensitization of HER-2/neu-over-expressing non-small cell lung cancer cell to chemotherapeutic drugs by tyrosine kinase inhibitor emodin. Oncogene 1996 12 571-576. [Pg.408]

See other pages where HER-2/neu is mentioned: [Pg.1011]    [Pg.1313]    [Pg.1320]    [Pg.1321]    [Pg.4]    [Pg.11]    [Pg.11]    [Pg.12]    [Pg.159]    [Pg.165]    [Pg.165]    [Pg.99]    [Pg.420]    [Pg.434]    [Pg.223]    [Pg.224]    [Pg.62]    [Pg.67]    [Pg.133]    [Pg.86]    [Pg.5]    [Pg.242]    [Pg.339]    [Pg.340]    [Pg.340]    [Pg.404]   
See also in sourсe #XX -- [ Pg.222 ]

See also in sourсe #XX -- [ Pg.497 ]

See also in sourсe #XX -- [ Pg.243 ]



SEARCH



HER-2/neu gene expression

HERS

Her-2/neu receptor

Herring

Neu

© 2024 chempedia.info